Yannick Frey
Research Subjects
Research Interests
Yannick Frey has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Hesso Farhan
Medical University of Innsbruck
2 shared publications - Monilola A. Olayioye
University of Stuttgart
2 shared publications Amin Alirezaylavasani
Precision immunotherapy alliance (PRIMA), Institute of Clinical Medicine, Department of Immunology, University of Oslo, Oslo, Norway
1 shared publication- Anders Aune Tveita
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
1 shared publication Andrea Hartner
Department of Pediatrics and Adolescent Medicine, University Hospital of Erlangen, D-91054 Erlangen, Germany
1 shared publicationAndrej Besse
Laboratory of Experimental Oncology, Department of Oncology and Hematology, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
1 shared publication
Latest Publications
- 28 October 2026
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 225 (12)
Beyond vesicles and tubules: What matters at ER exit sites?
Export of secretory proteins at ER exit sites (ERES) has been described to occur via COPII-coated vesicles, tubules, or tunnels. These models have not been considered to reflect the flexibility of ERES but rather as mutually exclusive mechanisms. Here, we overview these export mechanisms, discuss why they coexist, and hypothesize about the biological relevance of carrier geometry. Finally, we suggest experimental avenues to resolve the disagreement.
- 28 October 2026
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 225 (12)
Beyond vesicles and tubules: What matters at ER exit sites?
Export of secretory proteins at ER exit sites (ERES) has been described to occur via COPII-coated vesicles, tubules, or tunnels. These models have not been considered to reflect the flexibility of ERES but rather as mutually exclusive mechanisms. Here, we overview these export mechanisms, discuss why they coexist, and hypothesize about the biological relevance of carrier geometry. Finally, we suggest experimental avenues to resolve the disagreement.
- Open Access
- 9 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2237-2245
Targeting proteostasis in multiple myeloma through inhibition of LTK
Multiple myeloma (MM) cells secrete high levels of immunoglobulin and are therefore addicted to mechanisms that maintain proteome homeostasis (proteostasis). While proteasome inhibitors that target the degradative aspect of proteostasis have proven effective, only limited attempts have been made to target protein secretion. Here we show that the receptor tyrosine kinase LTK is a regulatory node in the proteostasis network that responds to secretory load and helps cells maintain a high secretory output. LTK is a highly similar paralog to ALK and by repurposing existing ALK inhibitors, we demonstrate that targeting LTK causes immunoglobulin retention, ER stress and subsequent apoptosis of primary MM cells, even in patients refractory to proteasome inhibitors. Thus, LTK is a novel therapeutic target in the biosynthetic pathway of proteostasis, with significant potential for MM treatment.
- 9 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2237-2245
Open AccessTargeting proteostasis in multiple myeloma through inhibition of LTK
Multiple myeloma (MM) cells secrete high levels of immunoglobulin and are therefore addicted to mechanisms that maintain proteome homeostasis (proteostasis). While proteasome inhibitors that target the degradative aspect of proteostasis have proven effective, only limited attempts have been made to target protein secretion. Here we show that the receptor tyrosine kinase LTK is a regulatory node in the proteostasis network that responds to secretory load and helps cells maintain a high secretory output. LTK is a highly similar paralog to ALK and by repurposing existing ALK inhibitors, we demonstrate that targeting LTK causes immunoglobulin retention, ER stress and subsequent apoptosis of primary MM cells, even in patients refractory to proteasome inhibitors. Thus, LTK is a novel therapeutic target in the biosynthetic pathway of proteostasis, with significant potential for MM treatment.